Different features of acute myeloid leukemia stem cell quantification in intensively treated patients
Year: 2025
Type: article
Abstract: In acute myeloid leukemia, the burden of CD34+CD38- leukemia stem cells (LSC) has prognostic value at diagnosis and after induction chemotherapy. Since different methods of LSC quantification have been proposed, we determined the prognostic value on overall survival and incidence of relapse of these methods across European LeukemiaNet (ELN) 2017 risk groups, using data from the HOVON-SAKK132 trial. In addition, we evaluated the optimal number of acquired white blood cells for accurate LSC detection and the prognostic value of individual LSC markers. Results show that it is essential to acquire at least 1x106 white blood cells in order to assess LSC-negativity accurately. Among various LSC markers, CD44 overexpression on CD34+CD38- cells was the only marker that was not statistically significant in our panel. Testing the impact of several published variations of LSC analysis on prognostic value for overall survival and cumulative incidence of relapse showed only marginal differences, demonstrating the robust prognostic value of LSC burden. For further clinical implementation, the optimal LSC assessment may differ among ELN risk groups. In conclusion, LSC burden is a robust prognostic factor and insight into the different methods of LSC definition can facilitate the clinical implementation. Trial registration EudraCT Number: 2013-002843-26.
Source: Haematologica
Authors: Lok Lam Ngai, Tom Reuvekamp, Diana Hanekamp, Fleur Janssen, Laura Oudshoorn-van Marsbergen, Jannemieke Carbaat-Ham, Maaike A.M. Hofland, Mona M.H.E. Fayed, Angèle Kelder, Willemijn J. Scholten, Alexander N. Snel, Costa Bachas, Jesse M. Tettero, Dimitri A. Breems, Thomas Fischer, Bjørn T. Gjertsen, Laimonas Griškevičius, Gunnar Juliusson, Arjan A. Van de Loosdrecht, Johan A. Maertens, Markus G. Manz, Thomas Pabst, Jakob R. Passweg, Kimmo Porkka, Peter J.M. Valk, Patrycja Gradowska, Bob Löwenberg, Gert J. Ossenkoppele, David C. De Leeuw, Jacqueline Cloos
Institutions: Cancer Center Amsterdam, Amsterdam UMC Location Vrije Universiteit Amsterdam, University of Amsterdam, Erasmus MC, Ziekenhuis aan de Stroom, University Hospital Magdeburg, Otto-von-Guericke-Universität Magdeburg, Haukeland University Hospital, Vilnius University, Vilnius University Hospital Santariskiu Klinikos, Skåne University Hospital, Universitair Ziekenhuis Leuven, University Hospital Zurich, Swiss Group For Clinical Cancer Research, University Hospital of Bern, University Hospital of Basel, Helsinki University Hospital, Erasmus MC Cancer Institute
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,157
OpenAlex ID: W4409969874